Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493165 | 1.00 | CA2 (0.57) | CA2CA1CA9CA5ACHRNA7 | |
| Hydrochloric Acid SCHEMBL20502486 | 0.98 | CA2 (0.55) | CA2CA1CA9CA5ACHRNA7 | |
| SCHEMBL27468836 | 0.83 | CYP1A2 (0.52) | CHRNA7CYP2A6NAPRTCYP1A2CYP2D6 | |
| SCHEMBL4245616 | 0.81 | CHRNA7 (0.58) | CHRNA7CYP2A6CYP1A2CYP2D6RECQL | |
| SCHEMBL496895 | 0.80 | NAPRT (0.53) | CHRNA7NAPRTCYP1A2CYP2D6RECQL | |
| SCHEMBL1271313 | 0.80 | NAPRT (0.48) | CHRNA7CYP2A6NAPRTCYP1A2CYP2D6 | |
| SCHEMBL1457306 | 0.80 | NAPRT (0.48) | CHRNA7CYP2A6NAPRTCYP1A2CYP2D6 | |
| SCHEMBL1271314 | 0.80 | CHRNB2 (0.50) | CHRNA7NAPRTCYP1A2CYP2D6CHRNB2 | |
| Hydrochloric Acid SCHEMBL1500992 | 0.78 | NAPRT (0.47) | CHRNA7CYP2A6NAPRTCYP1A2CYP2D6 | |
| SCHEMBL5696687 | 0.78 | CHRNB2 (0.50) | CHRNA7NAPRTCYP1A2CYP2D6CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250346922-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | TENAYA THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240336590-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2024-10-10 | — | — | US | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4364798-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | Annapurna Bio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | disclosed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| CN-1226231-A | Process for preparing 3-pyrroline-2-carboxylic acid derivative | BASF AG (DE) | 1999-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CA2 3641/4885CA1 3382/4885CA9 3326/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | CA2 3641/4885CA1 3382/4885CA9 3326/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | CA2 535/4885CA1 1069/4885CA9 1154/4885 |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | CA2 2202/4885CA1 1460/4885CA9 1823/4885 |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | HDAC6, HDAC1, HDAC2 | CA2 2202/4885CA1 1460/4885CA9 1823/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CA2 3603/4885CA1 2505/4885CA9 2932/4885 |
| US-20240336590-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | CA2 849/4885CA1 3222/4885CA9 546/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | CA2 3694/4885CA1 4880/4885CA9 4611/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | CA2 437/4885CA1 1453/4885CA9 2450/4885 |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | CA2 952/4885CA1 3105/4885CA9 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.